|
Adrenocortical carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, significant CYP2W1 protein expression was found in only one tumor sample (a testosterone-producing adrenocortical carcinoma) and not in any normal tissue.
|
27598485 |
2016 |
|
Squamous cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
KRT13, FAIM2 and CYP2W1 mRNA expression in oral squamous cell carcinoma patients with risk habits.
|
25735388 |
2015 |
|
Adenocarcinoma of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analysis of CYP2W1 expression in the colon adenocarcinoma cell line HCC2998 revealed that the gene expression can be induced by e.g. the antitumor agent imatinib, linoleic acid and its derivatives.
|
25844926 |
2015 |
|
Hyperglycemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Tobaco, obesity and hyperglycemia significantly increased the risk of BCa in the patients carrying variant genotypes of CYP2W1 (P<0.05).
|
22631658 |
2012 |
|
Obesity
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Tobaco, obesity and hyperglycemia significantly increased the risk of BCa in the patients carrying variant genotypes of CYP2W1 (P<0.05).
|
22631658 |
2012 |
|
Adrenal Gland Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
No or very low CYP2W1 mRNA levels were detected in fetal and adult human tissues, expression was however seen in 54% of human tumor samples investigated (n=37), in particular colon and adrenal tumors.
|
16426568 |
2006 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
Quantitative RT-PCR analysis of these candidates revealed that APin protein (APIN), taxol resistance-associated gene 3 (TRAG3), cytochrome P450, family 2, subfamily W, polypeptide 1 (CYP2W1), melanoma inhibitory activity (MIA), matrix metalloproteinase-10 (MMP-10), dickkopf homolog 4 (DKK4), GW112, regenerating islet-derived family, member 4 (REGIV), and HORMA domain-containing 1 (HORMAD1) were expressed much more highly in GC than in 14 kinds of normal tissues.
|
16331256 |
2006 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Quantitative RT-PCR analysis of these candidates revealed that APin protein (APIN), taxol resistance-associated gene 3 (TRAG3), cytochrome P450, family 2, subfamily W, polypeptide 1 (CYP2W1), melanoma inhibitory activity (MIA), matrix metalloproteinase-10 (MMP-10), dickkopf homolog 4 (DKK4), GW112, regenerating islet-derived family, member 4 (REGIV), and HORMA domain-containing 1 (HORMAD1) were expressed much more highly in GC than in 14 kinds of normal tissues.
|
16331256 |
2006 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
CYP2W1 expression level was suggested to serve as an independent prognostic biomarker in colorectal cancer and hepatocellular carcinoma.
|
27690753 |
2017 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The relative mRNA expression of CYP2W1 was significantly higher in HCC tissues than in adjacent noncancerous tissues (P < 0.001).
|
24801906 |
2014 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Expression of CYP2S1 and CYP2W1 in breast cancer epithelial cells and modulation of their expression by synthetic methoxy stilbenes.
|
31561186 |
2019 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Expression of CYP2S1 and CYP2W1 in breast cancer epithelial cells and modulation of their expression by synthetic methoxy stilbenes.
|
31561186 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine the mRNA expression patterns of four cytochrome P450 genes (CYP2W1, 3A5, 4F11 and 8A1) in Mexican women with breast cancer.
|
22938436 |
2012 |
|
Malignant neoplasm of breast
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In this report, and for the first time in the literature, we analyzed the rs3735684 (7021 G>A), rs11553651 (15016 G>T) and rs56195291 (60020 C>G) polymorphisms in the CYP2W1, 4F11 and 8A1 genes in patients with BCa and in healthy Mexican women to identify a potential association between these polymorphisms and BCa risk.
|
22631658 |
2012 |
|
Breast Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In this report, and for the first time in the literature, we analyzed the rs3735684 (7021 G>A), rs11553651 (15016 G>T) and rs56195291 (60020 C>G) polymorphisms in the CYP2W1, 4F11 and 8A1 genes in patients with BCa and in healthy Mexican women to identify a potential association between these polymorphisms and BCa risk.
|
22631658 |
2012 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine the mRNA expression patterns of four cytochrome P450 genes (CYP2W1, 3A5, 4F11 and 8A1) in Mexican women with breast cancer.
|
22938436 |
2012 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
CYP2W1 expression level was suggested to serve as an independent prognostic biomarker in colorectal cancer and hepatocellular carcinoma.
|
27690753 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer.
|
24088132 |
2013 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
CYP2W1 variant alleles in Caucasians and association of the CYP2W1 G541A (Ala181Thr) polymorphism with increased colorectal cancer risk.
|
20602611 |
2010 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity.
|
20805301 |
2010 |
|
Malignant tumor of colon
|
0.050 |
Biomarker
|
disease |
BEFREE |
Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1.
|
26787547 |
2016 |
|
Malignant tumor of colon
|
0.050 |
Biomarker
|
disease |
BEFREE |
This information thus underline the colon cancer specificity of CYP2W1 enzyme expression and has implications for the development of anti-colon cancer therapies based on CYP2W1 as a drug target, since 2W1-dependent bioactivation of prodrugs for CYP2W1 will not take place in normal adrenal tissue or other non-transformed tissues.
|
27598485 |
2016 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1.
|
26787547 |
2016 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
This information thus underline the colon cancer specificity of CYP2W1 enzyme expression and has implications for the development of anti-colon cancer therapies based on CYP2W1 as a drug target, since 2W1-dependent bioactivation of prodrugs for CYP2W1 will not take place in normal adrenal tissue or other non-transformed tissues.
|
27598485 |
2016 |
|
Malignant tumor of colon
|
0.050 |
Biomarker
|
disease |
BEFREE |
Cells expressing CYP2W1 suffer rapid loss of viability following treatment with ICT2705 and ICT2706, whereas the CYP2W1-positive human colon cancer xenografts display arrested growth in the mice treated with ICT2706.
|
23589180 |
2013 |